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ABSTRACT
The notable increase in drug-resistant infections and the failure of the most potent antibiotics to
establish their curative effect without side effect have presented a serious need for the discovery of
new therapeutic agent and the study of dietary implications on the mode of entry of these thera-
peutic agents in the human system. This review provides insight into the forms andmodes of action,
and roles of beneficial but limited and underutilized antimicrobial peptides for use in dietary formu-
lations, with particular focus on the technologies employed for their discovery aswell as their dietary
efficacy. The wide spectrum of activities of these peptides will allow the opportunity to explore their
benefits as dietary supplements and additives.
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Antibiotics have been widely used for the prevention
of diseases and growth improvement in animalmodels
(de la Fuente-núñez et al. 2017). The emergence and
rapid dissemination of antibiotic-resistant microbes
pose substantial risks for human health. It is predicted
that by 2050, global human deaths due to antibiotic-
resistant infections will reach 10millionmore than the
current death toll associated with different forms of
cancer (Roy and Trinchieri 2017). This is exacerbated
by the fact that the number of newly approved antibi-
otics has significantly and steadily decreased in the last
30 years (Martens and Demain 2017). In line with this,
an urgent need to develop novel antimicrobial agents,
including alternative drugs-based antimicrobial pep-
tides (AMPs) and other compounds are imperative
(Chandra et al. 2017).
AMPs, also known as host defense peptides (HDPs)
are part of the innate immune response found among
all classes of life and aremostly found in the tissues and
organs that are exposed to airborne pathogens (Wang
2017). The uniqueness of AMPs is inherent in the fact
that they target the cell membrane which is ubiquitous
inmicroorganisms, unlike the conventional antibiotics
which target specific cellular activities (e.g. synthesis of
DNA, protein, or cell wall). Another vital role of AMPs
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is their rapid killing effect (within seconds) after initial
contact with the cell membrane (Mai et al. 2017).
To date, more than 5,000 AMPs have been dis-
covered in bacteria, protozoans, fungi, plants, insects,
and animals or chemically synthesized (Wang 2017;
Mishra et al. 2017). These peptides are generally
between 5 and 100 amino acids in length which
include two or more positively charged residues pro-
vided by arginine, lysine or, in acidic environments,
histidine, and a large proportion (generally >50%)
of hydrophobic residues (Jia et al. 2016). These pep-
tides possess potent, broad-spectrum potential which
demonstrates their capacity as novel therapeutic agents
against bacteria, viruses, fungi and cancerous cells
(Deslouches and Di 2017). This is due to their abil-
ity to rupture and destabilize biological membranes of
pathogens, thereby forming transmembrane channels.
They also have the tendency to enhance immunity by
functioning as immunemodulators which impact sev-
eral advantages to these peptides over conventional
antibiotics (Mishra et al. 2017).
Furthermore, AMPs offer great promise because
they combat low and high-affinity pathogen targets
suggesting the development of very limited or no
pathogen resistance towards them as opposed to con-
ventional antibiotics. This property of AMPs makes
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
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Figure 1. Overview of AMPs dietary supplement formulation.
it more difficult for target microbes to defend them-
selves by a single resistance mechanism (Stach et al.
2014; Haney et al. 2017;Mishra et al. 2017). Hence, the
importance to study their modes of action and insights
into their discovery processes and therapeutic rele-
vance in diets. Functional foods fortified with AMPs
can play a role in disease prevention and health pro-
motion. Also, due to irritation and other side effects, it
is easier and safer to consume drugs in form of foods
than oral administration. This review addresses the
need for AMPs development for use as dietary sup-
plements for human for therapeutic purposes against
pathogens (Figure 1).
Antimicrobial peptides
AMPs are found in nearly all life forms and are pro-
duced by all organisms ranging frombacteria to plants,
vertebrates, and invertebrates (Kumar et al. 2018). In
bacteria, theAMPs benefit individual species by killing
other bacterial species that may compete for nutrients
and the same environmental niche. As a class of bacte-
ria AMPs (class-1 bacteriocins), Lantibiotics are post-
translationally modified AMPs (e.g. Nisin) contain-
ing non-proteinaceous amino acid lanthionine with
a broad range of anti-bacterial activities. Other class
II bacteriocins category includes non-lantibiotics (e.g
bacteriocin-like inhibitory substance (BLIS)), which
have bactericidal activities against limited range of
bacteria (Alvarez-Sieiro et al. 2016). One of the first
AMPs isolated and characterized was nisin from Lac-
tococcus lactis in 1947 (Mattick and Hirsch 1947).
With minimum inhibitory concentration in the range
of nanomolar, nisin is effective against Gram-positive
bacteria and has been used as a food preservative for
50 years with no significant development of resistance
(Jenssen et al. 2006). Another bacteria AMPs stud-
ied for their possible use against antibiotic-resistant
Gram-positive bacteria is mersacidin (Chatterjee et al.
1992). Plant, animal, and fungi have been reported
as the origin of naturally discovered AMPs (Kumar
et al. 2018). Generally, AMPs are cationic, amphi-
pathic and have broad-spectrum activity (Table 1)
(Patterson-Delafield et al. 1981; Okada and Natori
1983; Zasloff 1987). Some of the roles of AMPs include
innate immunity, immune modulation, and control
of inflammation (Bowdish et al. 2005; Nijnik and
Hancock 2009; Haney and Hancock 2013; Hilchie
et al. 2013; Hancock et al. 2016). Eukaryotic AMP
cecropins have been isolated in silk moth and fruit
flies (Iwanaga andKawabata 1998; Bachère et al. 2004).
Tachyplesin was reported to have activities against
both bacterial and fungal (Tincu and Taylor 2004)
while polyphemusin is potent against viruses, bacterial
and fungal (Masuda et al. 1992; Tincu and Taylor
2004).
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Table 1. Broad-Spectrum Activity of Antimicrobial peptides from AMP database (APD).
AMP Name Amino acid sequences Source ID Function
Dermaseptin GLWSKIKEVGKEAAKAAAKAAGKAALG
AVSEAV
Phyllomedusa bicolor AP00001 Antibacterial
Abaecin YVPLPNVPQPGRRPFPTFPGQGPFNPK
IKWPQGY
Apis mellifera L. AP00002 Antibacterial
Ct-AMP1 NLCERASLTWTGNCGNTGHCDTQCRN
WESAKHGACHKRGNWKCFCYFDC
Clitoria ternatea AP00004 Antifungal
Andropin VFIDILDKVENAIHNAAQVGIGFAKPFEK
LINPK
Drosophila melanogaster AP00005 Anti-Gram+
Aurein GLFDIIKKIAESF Litoria aurea AP00013 Anti-cancer




Pleurotus citrinopileatus AP00023 Anti-viral and Anti-cancer
Alloferon HGVSGHGQHGVHG Calliphora vicina AP00025 Anti-viral and Anti-cancer
Aurein 2.4 GLFDIVKKVVGTLAGL Litoria raniformis AP00017 Anti-cancer
Lactoferricin B FKCRRWQWRMKKLGAPSITCVRRAF Bos Taurus AP00026 Anti-HIV and Anti-cancer
Figure 2. Various structures of AMPs.
Due to the increasing growth of antibiotics resis-
tance, AMPs with multiple modes of action have
been considered as alternatives to inhibit or combat
pathogens. Two methods have been put into con-
sideration prior to the development of AMPs. These
methods include (1) theN-terminal modification with
lipid acid which significantly improved the cationic
AMPs’ antibacterial and antifungal activities with sec-
ondary structure changes. (2) The combination of in
silico computational screening tool and experimental
activity test for AMPs optimization. Both the chemical
modification and in silico optimizationwould assist the
potent antimicrobial agents’ development.
Structural categories of AMPs
There are variety of approaches used for the clas-
sification of AMPs. AMPs are classified based on
biosynthesis architecture (e.g. enzymatic, gene coded
or synthetic) or molecular target (e.g. membrane tar-
geting or cell penetrating target) or structure and
activity-based classification. Here, AMPs have been
categorized into subgroups on the basis of their
amino acid composition and structures because AMPs
structures have been said to be related to their
functions. The secondary structural architecture of
these vital molecules includes α-helical, mixed α/β ,
β-stranded, and extended structures with loops or
hairpins (Figure 2). Their β architecture is due to the
presence of two or more disulfide bonds whilst the
extended structure is contributed by a single disul-
fide bond and/or cyclization of the peptide chain
(Kumar et al. 2018). However, some AMPs do not
belong to any of these aforementioned groups (Gabere
and Noble 2017) whilst some are composed of two
different structural components (Jia et al. 2016). Cer-
tain AMPs form active structures only during inter-
action with membranes of target cells. An example
of this is indolicin that shows a change in confor-
mation during interaction with DNA observable with
decreased fluorescence intensity and a slight shift in
wavelength of maximum emission (Le et al. 2017),
globular and amphipathic conformation in an aqueous
solution and a wedge-shaped conformation in a lipid
bilayer environment (Li et al. 2017). Generally, the
hydrophilic amino acid residues of these peptides align
along one side of their structurewhilst their hydropho-
bic amino acid residues are formed along the opposite
side of a helical molecule (Nordström and Malm-
sten 2017). These structural characteristics contribute
to their amphipathicity that allows for partitioning
into the membrane lipid bilayer, thereby enhancing
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their antimicrobial activities, thus impacting effective
membrane permeability on a range of cytoplasmic
targets (Bechinger and Gorr 2017).
Natural and artificial production of AMPs
Synthesis of most natural AMPs is carried out by spe-
cific cells within prokaryotic and eukaryotic organisms
including viruses. These AMPs are produced either
by ribosomal translation of mRNA through genetic
coding in all life forms or by non-ribosomal peptide
synthesis mainly in bacteria (Felgueiras and Amorim
2017). Lymph, epithelial cells in gastrointestinal and
genitourinary systems (Zeth and Sancho-Vaello 2017),
phagocytes (Ramesh et al. 2016) and lymphocytes
(Haney et al. 2017) are some of the eukaryotic cells
which are involved in the production of AMPs as
ribosomal-gene encoded pre-peptides. Apart from the
production in innate immune responses, AMPs can
be produced by the influence of the host’s inflamma-
tory responses during infection (Riool et al. 2017).
This is evident from the treatment of mammals with
bacterial lipopolysaccharide (LPS) antibiotics for host
immunity where AMP production was induced, thus
reducing the inflammatory response (Mangoni et al.
2016). Certain AMPs such as CAP18 (Kuroda et al.
2017), CAP35 (Moravej et al. 2018), and a lactoferrin-
derivative (Lu et al. 2016) block LPS-induced cytokine
release by macrophages. In contrast to this inflamma-
tory regulation, antibiotics do not have this regulation
on the inflammatory response of the host immune sys-
tem; and LPS secretion results in an over-reaction of
the host immune system, causing sepsis (Li et al. 2017).
It is relatively easy to modify the structure of AMPs
because of their amino acid composition (Wang 2017).
This is necessary for modification of existing AMPs
and designing new synthetic ones for a potential
change of targets and improved stability against pro-
teases (Nordström and Malmsten 2017; Zorzi et al.
2017). Artificial synthesis is carried out by chemical
synthesis using fully synthetic peptides (Zorzi et al.
2017) or recombinant expression systems (Haney et al.
2017). Despite these advantageous features of AMPs,
certain expertise is required for the blueprint design
or discovery of AMPs so that certain shortcomings are
not introduced into their end products such as poten-
tial toxicity to humans (Deslouches and Di 2017),
sensitivity to harsh environmental conditions such as
proteases and extreme pH (Guidotti et al. 2017), lack
of selectivity against specific strains (Wang et al. 2017),
high production costs (Felício et al. 2017), folding
issues of some large AMPs (Logashina et al. 2017),
reduced activity when used for surface coating (Wang
2017), and bacterial resistance to some AMPs (Jia et al.
2016). Given the limitations associated with the chem-
ical synthesis of AMPs, there is a need to explore
more sensitive options including the use of in silico
technologies for more sensitive, specific and accurate
options towards their targets. These technologies con-
sider the size, charge, hydrophobicity, amphipathicity,
and solubility of AMPs tomodify their activity and tar-
get spectrum for the production of novel AMPs and
mutagenesis of existing ones.
Modes of action of AMPs
AMPs have varying modes of action by which they kill
target microbes (Figure 3) (Bechinger and Gorr 2017;
Wang 2017). AMPs possess multiple activities includ-
ing anti-Gram-positive bacterial, anti-Gram-negative
bacterial, anti-fungal, anti-viral, anti-parasitic, and
anti-cancer activities. These molecules interfere pri-
marily with the cytoplasmic membrane of the target
but can also interact with DNA, protein synthesis, pro-
tein folding, and cell wall synthesis (Kumar et al. 2018).
For bacteria, the initial contact with the peptide is
electrostatic, as most bacterial surfaces are anionic, or
hydrophobic. AMPs attach to and insert into mem-
brane bilayers forming pores by ‘barrel-stave’, ‘carpet’
or ‘toroidal-pore’ mechanisms due to their amino acid
composition, amphipathicity, cationic charge and size.
They may also bind intracellular molecules which are
crucial to living cells causing inhibition of cell wall syn-
thesis, alteration of the cytoplasmicmembrane, activa-
tion of autolysin, inhibition of DNA, RNA, and protein
synthesis, and inhibition of certain enzymes (Mishra
et al. 2017). For instance, buforin II can diffuse into
cells and bind to DNA and RNAwithout damaging the
cell membrane (Haney et al. 2017). Drosocin, pyrrho-
coricin, and apidaecin are other examples of such
AMPs. These AMPs have 18–20 amino acid residues
with an active site for their intracellular target (Felício
et al. 2017). Other AMPs can block cell wall syntheses
such as nicin, Gramicidin S, and PGLa (Mangoni et al.
2016; Mishra et al. 2017). Generally, their antimicro-
bial activity is determined by measuring the minimal
inhibitory concentration (MIC), which is the lowest
concentration of a drug that inhibits the growth of the
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Figure 3. Modes of action for cellular antimicrobial peptide activity.
Figure 4. Mechanisms of linear AMPs interacting with lipid bilayers. Image modified from Giuliani et al. (2008) (Copyright License No:
4686040911180).
pathogen (Haney et al. 2017). It is therefore not sur-
prising that AMPs have been used for their therapeutic
abilities against bacteria and other pathogens (Zhang
et al. 2017) and diagnostic purposes for HIV (Tincho
et al. 2016).
Techniques used to elucidate AMP function
The exactmechanism bywhich antimicrobial peptides
establish their effect remains unclear. Three major
mechanisms by which they establish their actions
include the formation of toroidal pore, carpet, and
barrel-stave (Figure 4). Although the specificity of
these mechanisms differs, they work by allowing
peptide-induced membrane rupture and this gives
rise to cytoplasmic leakage which ultimately leads to
death of the target organisms. Several methods have
been used to determine the mechanisms of antimi-
crobial peptide activity (O’Driscoll et al. 2013; Hein
et al. 2015). These methods include dual polarization
interferometry, solid-state NMR which has provided
an atomic-level resolution explanation of membrane
disruption by AMPs (Haney et al. 2017) (Schnabel
2017; Wei et al. 2017). X-ray crystallography has
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been employed to delineate how the family of plant
defensins rupturemembranes by identifying key phos-
pholipids in the cell membranes of the pathogen (Poon
et al. 2014; Järvå et al. 2018). Microscopy is used to
visualize the effects of AMPs on microbial cells (Boge
et al. 2017). Atomic emission spectroscopy is used to
detect loss of intracellular potassium (an indication
that bacterial membrane integrity has been compro-
mised (Chen et al. 2015)). Fluorescent dyes are used to
measure the ability of AMPs to transverse membrane
vesicles (Figure 3) (Scheinpflug et al. 2017). Ion chan-
nel formation is used to assess the formation and sta-
bility of an AMP-induced pore and circular dichroism
and orientated circular dichroism is used to measure
the orientation and secondary structure of an AMP
bound to a lipid bilayer (Müller et al. 2017).
Many AMPs have the potential to fold into amphi-
pathic a-helices with hydrophilic and hydrophobic
sides (top, left). This conformation is schemati-
cally represented as an amphiphilic cylinder, with
hydrophobic (red) and hydrophilic (blue) halves.
AMPs bind to the membrane surface with the
hydrophobic side groups anchored in the hydropho-
bic lipidic core of the bilayer, leading to different
outcomes (center). The wormhole (or toroidal) pore
model (bottom, left) as proposed for megainin (Bot-
tom, center) Barrel-stave pore model, as proposed
for alamethicin, a peptide antibiotic produced by the
soil fungus Trichoderma viride. (Bottom, right) Car-
pet model: antimicrobial peptides crowd on the mem-
brane’s surface and lead subsequently to micellation.
Modified from Sani et al. (2017).
In Silico predictions of AMPs
Several bioinformatics tools have been developed to
generate new templates with appealing antimicrobial
properties with the aim of discovering highly active
peptide compounds with low cytotoxicity. It is imper-
ative to explore these tools given to demonstrate the
connection between the structural classes of AMPs,
mode of actions, and the potency of activity among the
series of host targets. Thus AMPs with similar struc-
tures can have a distinctly different mode of action
and target cells. A structure-based precise prediction
of activity, mode of action, and host range can only be
possible if certain general design principles are con-
sidered. One of such is the length of an AMP which
allows it to traverse the bilayer of the cell membrane
in the barrel-slave model (Mishra et al. 2017) and also
affect its cytotoxicity. The net charge is another main
factor for the initial interaction with the cell mem-
brane which when altered can abolish the selective
killing of microbes (Bechinger and Gorr 2017). Helic-
ity, although less important, when reduced by incorpo-
rating D-amino acids into the primary sequence has
been shown to lower the hemolytic effect, while the
antimicrobial activity was retained (Migoń et al. 2018).
Ifmore than 50%of amino acid residues of anAMP are
hydrophobic, there is an increased positively charged
side of the AMP below a threshold which increases
its antimicrobial activity (Bechinger and Gorr 2017)
and vice versa (Mishra et al. 2017). Amphipathicity
is another property of AMPs that ensure their activ-
ity and interaction with microbial membranes and has
been shown to be more important than hydrophobic-
ity for binding to microbial membranes (Felício et al.
2017). This is because it confers a strong partition
on AMP-membrane interaction for the target cells. In
other words, if the AMP molecules aggregate, it will
lose its ability to interact with the cell membrane.
Mutagenesis affects solubility in such a way that,
if handled carelessly, can increase the dimerization of
AMPs. For example, substituting a Lys residue on the
non-polar face of a hybrid AMP prevents dimeriza-
tion and leads to reduced hemolytic activity. Thus, loss
of dimerization makes this AMP more effective for
its incorporation into microbial membranes (Thamri
et al. 2017). It is therefore imperative to predict and
construct a functional peptide using in silico technolo-
gies, to achieve more accurate results. Application of
these technologies to analyze the details of the fold-
ing of AMP molecules and interaction with target
cells may be a promising approach to improve cur-
rent trial and error methods. These types of artificial
AMP design strategies hold the potential for develop-
ing new synthetic peptides against antibiotic-resistant
pathogens (Riool et al. 2017).
Support VectorMachine (SVM)
SVMmethod is a polynomial kernel function which is
regarded as the best model for classification of AMPs
with excellent accuracy, sensitivity, specificity, and the
Mathews Correlation Coefficient measure when used
in a linear and nonlinear classification (Gabere and
Noble 2017). It uses algorithms to analyze data used
for classification and regression analysis. It constructs a
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hyperplane or set of hyperplanes in a high- or infinite-
dimensional space, which can be used for classifica-
tion, regression, or other tasks like outliers identifica-
tion. The hyperplane that has the largest distance to
the nearest training data point of any class is a good
separation since the larger the margin, the lower the
generalization error of the classifier (Hastie et al. 2015).
SVM is a powerful tool for solving problems in clas-
sification, function estimation and density estimation
with no prior assumptions about data and underly-
ing distribution. Also, it does not necessitate a large
number of training data to avoid overfitting. For this
reason, it has been widely applied in biological and
other sciences to classify proteins with up to 90% of the
compounds classified correctly (Meher et al. 2017).
HiddenMarkovModels (HMMER)
The Hidden Markov Models (HMMER) algorithm,
used on Ubuntu LTS operating system which is based
on the Linux kernel, has multiple modules to perform
optimally using several command lines. HMMER only
requires the sequences of experimentally validated
biomolecules for the construction of models. These
models will display their features based on the motifs
of the input sequences and would have the desired
activity against the specific target (Porto et al. 2017; Liu
et al. 2017). The high sensitivity of the HMMER pro-
files is due to the combination of the scoring system
and the low cut-off E-value calculated during the pro-
teome sequences scanning steps. The E-value provides
more information about the probability that predicted
AMPs are true positives or false negatives (Hoppen-
brouwers et al. 2017; Khater et al. 2017; Lopes et al.
2017). The use of the HMMER algorithm is deemed
an appropriate tool which enables amore sophisticated
search for novel peptides through proteome sequence
scanning. Several AMPs discovered through this pro-
cess, have been proven to detect certain diseases (Tin-
cho et al. 2016).
Gap Local Alignment ofMotifs 2 (GLAM2)
GLAM2 is designed for certain bio-sequence motifs
that exhibit mutational changes either with insertion
or deletion because it allows gaps within the AMPs.
Discovery of gapped motifs is intrinsically more dif-
ficult than un-gapped motifs, therefore performing
a simpler gapless motif analysis is recommended.
Amino acid residuesmay be inserted between gaps and
this assumes that their identity is irrelevant. GLAM2
reports a score for each motif that it discovers, with
higher scores indicating stronger motifs and better
matches to the overall motif. GLAM2 does not search
for multiple distinct motifs but performs replicates in
an attempt to discover motif with 10 times possibility
strength, and displays the results in order of bit and
E value scores. If the top few results are similar, this
may be regarded as successful replication and a rerun
is recommended to increase the ‘number of iterations’
parameters (Vannini et al. 2017). However, GLAM2
has difficulty adjusting the motif width when there are
many short sequences. It should be noted that both
protein and DNA motifs are often shorter than the
defaults (50) used by GLAM2 for ‘maximum num-
ber of aligned columns’ and ‘maximumwidth’ (Brázda
et al. 2018).
Quantitative Structure-Activity Relationship (QSAR)
QSAR plays a vital role in modern drug design since
it is cost-effective, much easier to handle, faster and
more amenable to automation. The QSAR model is
built on the mathematical foundation of statistical and
chemometric techniques. It is a computational screen-
ing model that is used whenever compounds with
particular biological activity are known. It correlates
macroscopic target properties with computed atom-
based descriptors derived from the spatial representa-
tion of the molecular structures. Although QSAR per-
forms a positive role in predicting and associating the
biological features of molecules in many instances and
conditions, it suffers from serious shortcomings given
as follows: deficiency in sufficient number of training
molecules, generation of only 2-D structuremolecules,
shortage of parameters for comparing drug-receptor
relationships such as Hammett constant, lack spe-
cific physiochemical parameters, absence of repre-
sentation of stereochemistry, unavailable unique dis-
solution with high risk of failure and chance cor-
relations, requirement of substituent constants and
chemistry utilized to design a molecule before action,
and absence of suggestion to synthesize a new com-
pound through classical QSAR equations with no
graphical result (E Greber and Dawgul 2016). Except
these shortcomings are given adequate consideration,
QSAR will not design AMPs of desired specificity and
accuracy.
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Linear Discriminant analysis (LD)
Linear Discriminant Analysis (LDA), formulated by
Ronald A. Fisher (1938), is used to reduce dimen-
sionality in the pre-processing step for pattern-
classification and machine learning applications
(Fisher 1938). The steps involved in performing
the LDA include: compute the d-dimensional mean
vectors for the different classes from the dataset,
compute the scatter matrices (in-between-class and
within-class scatter matrix), compute the eigenvectors
(e1,e2, . . . ,ed1) and corresponding eigenvalues (λ1,
λ2, . . . ,λd) for the scatter matrices, sort the eigen-
vectors by decreasing eigenvalues and choose k eigen-
vectors with the largest eigenvalues to form a d×k
dimensional matrix W (where every column repre-
sents an eigenvector), and use this d×k eigenvector
matrix to transform the samples onto the new sub-
space. This can be summarized by the matrix multi-
plication: Y = X×W(where X is an n×d-dimensional
matrix representing then samples, and y are the trans-
formedn×k-dimensional samples in the new subspace
(Han et al. 2017)).
Random forest
Random forest, also known as random decision for-
est, is a method used for classification and regression
by constructing a multitude of decision trees at train-
ing time, using themodal class (classification) ormean
prediction (regression) of the individual trees (Man-
avalan et al. 2018). This algorithm contains the prelim-
inary decision tree step, tree bagging, random forest
step, and extra tree steps. The preliminary tree step
involves an off-the-shelf procedure for data mining
because it is invariant and robust but seldom inac-
curate (Abdallh et al. 2016). Tree bagging decreases
variance without leading to bias. In other words, the
prediction of a single tree is sensitive to noise in its
training set while training many trees in a single tree
would give strongly correlated trees. Random forest
step gives accuracy for the correlation of the trees in
a bootstrap sample. Thus, creating extra trees is a ran-
domized step yield extremely randomized trees. These
are then trained using bagging and random subspace
method with top-down splitting to select a random
value feature’s empirical range. Random forest predic-
tors naturally lead to a dissimilarity measure among
the observations which are then measured between
unlabelled data with the idea to construct a random
forest predictor that distinguishes the ‘observed’ data
from suitably generated synthetic data (Meher et al.
2017).
SlidingWindow (SW)
Sliding Window (SW) is created to solve inherent
problems such as high memory bandwidth require-
ments, segregation of the memory space and cen-
tralized control of switching functions which are
associated with present methods used in handling
packet biological data traffic efficiently. This method
introduces a switch architecture to overcome these
problems facing the scalability of shared-memory
switches (Liu et al. 2018). It makes use of a wide
range of coincidental memory modules that are
logically divided by all input and output lines to
store and execute data packets. The special ability
to accomplish parallel operation and the simplic-
ity of the control functions make this technique a
better method for prediction of AMPs (Pane et al.
2017).
Sequence alignment and feature selectionmethods
Sequence Alignment and Feature Selection methods
were developed since most tools in Bioinformatics
do not have the function to identify which features
are optimal for accurately predicting and meaning-
fully interpreting their biological implications. In the
feature selection method, each peptide will be coded
with several features, including amino acid composi-
tion (Meher et al. 2017) and pseudo amino acid com-
position (Gabere and Noble 2017) that incorporated
electrostatic charge, codon diversity, molecular vol-
ume, polarity, and secondary structure (W. Chen et al.
2016) while the sequence alignment method uses the
BLASTP function. BLASTP (Bhadra et al. 2018) was
used to predict AMPs, which can be described with a
query peptide P and the training set, then the high-
scoring segment pairs (HSPs) score between the query
peptide and each peptide in the training set are cal-
culated by BLASTP with default parameters. Sequence
Alignment would incorporate sensitivity but cannot
deal with much data accurately and this is comple-
mented by the Feature Selection method (Liu et al.
2017).
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Dietary consequences of AMPs as therapeutic
agents
The widespread distribution and abundance of AMPs
in living organisms underscore their critical role in
innate immunity as antimicrobial and immunomodu-
latory agents (Wang 2017). There are numerous AMPs
currently under clinical development for therapeu-
tic indications besides antimicrobials or antifungal
agents. To mention a few, LL-37 has recently been
evaluated in a clinical trial as a local treatment to
enhance healing of venous leg ulcers (Grönberg et al.
2014). Although the mechanisms by which LL-37 pro-
motes wound healing are not fully understood but
may involve several wound repair components such as
re-epithelialization, angiogenesis, and inflammation.
Apart from this, PXL01 has been explored for its pre-
vention of post-surgical adhesion formation in con-
nection to hand surgery, besides its anti-infection roles
(Wiig et al. 2014).
Studies are ongoing to use AMPs to increase their
endogenous production by the body in order to boost
the innate immune responses and thereby combating
infections. For instance, vitamin D has been evaluated
for its modulatory expression on several AMPs appli-
cability for the treatment of infections in several ongo-
ing trials (Wang 2017). However, the anti-infection
activity of AMPs is highly sensitive to environmen-
tal conditions, which results in discrepancies between
in vitro versus in vivo efficacy and makes the accurate
prediction of anti-infection properties in a clinical sit-
uation very difficult. This has been described in several
reports where the in vivo antimicrobial properties of
AMPs in experimental animal models appear inactive
or minimally active in the presence of physiological
salt concentrations evaluated in minimum inhibitory
concentration (MIC) (Radzishevsky et al. 2007; Jen-
nings et al. 2014; Krizsan et al. 2014; Ageitos et al. 2017;
Haney et al. 2017). For example, the presence of car-
bonates dramatically increases the sensitivity of AMPs
in both Gram-positive and Gram-negative bacteria
(Gong et al. 2017).
Furthermore, certain AMPs derived from food pro-
teins (e.g milk) which are harmless substances have
been discovered to have immense advantage for use
in medicine and food industry (Sah et al. 2018).
These advantages transcend the nutritive value to be
derived from them with possible resource to improve
the innate defence of the organisms against invading
pathogens. Examples of these proteins are lactoferrin
(Liu et al. 2018) and lysozyme (Wu et al. 2018) which
are bactericidal and have been modelled through the
process of ‘tailoring and modelling’ as food supple-
ments. Other examples include ovotransferrin, alpha-
lactalbumin and beta-lactoglobulin which are prod-
ucts of proteolytic digestion of food proteins which
are multifunctional molecules with physiological roles
(Chalamaiah et al. 2018). Also, pyroglutamyl leucine, a
peptide present in protein hydrolysates and fermented
foods, has been isolated for oral administration at
0.1mg/kg body weight in different animal models
(Shirako et al. 2019). It has been said to function in the
attenuation of hepatitis, colitis and dysbiosis, a term
used for microbial imbalance or maladaptation on or
inside the body (Sato 2018).
Moreover, the low metabolic stability of AMPs,
which is an inherent risk of therapeutic peptides in
general, is considered another key factor limiting their
clinical application. Peptide drugs are subjected to
pre-systemic enzymatic degradation and poor pen-
etration in intestinal mucosa thereby limiting their
bioavailability during oral administration. Also, the
rapid degradation by proteolytic enzymes in blood
plasma and rapid removal of AMPs from the circu-
lation by the liver and kidneys are negatively affected
by their short half-life during intravenous injection
(Zhang et al. 2017). It is believed that their use as
food supplements would enhance their therapeutic
efficacy. Yoon et al. (2013)investigated the effect of
dietary supplementation of basal diet with antimicro-
bial peptide-P5 (AMP-P5) on weanling pig nutrition;
this enhanced the peptide with improved growth per-
formance and total tract nutrients assimilation poten-
tial with reduced coliforms inweaning pigs. This result
is in line with the work of Xiong et al. (2014) which
reported that the addition of AMPs to the basal diet
had positive effects on growth action, ameliorative
occurrence of diarrhea, and a large survival rate of
weaned pigs.
Furthermore, Gadde et al. (2017), investigated the
effects of antimicrobial peptide-A3 (AMP-A3) at vary-
ing concentration to the basal diet on the growth
performance, nutrient retention, intestinal microflora
and intestinal morphology of broilers fed with basal
diet. The result showed that 90mg/kg AMP-A3 has
the best performance which can be used as a poten-
tial antimicrobial growth promoter. In addition, Liu
et al. (2017) reported the effects of the mixture of feed
FRONTIERS IN LIFE SCIENCE 87
Table 2. Some antimicrobial peptides (AMPs) used as food supplements, their biological roles and mechanism of action.
AMPs used in Diets Origin of the AMPs Biological Action Mechanism of Action Reference
LL-37 Homo sapiens Wound healing re-epithelialization, angiogenesis,
and inflammation
(Grönberg et al. 2014)
PXL01 Homo sapiens Hand surgery enhancer Post-surgical adhesion (Wiig et al. 2014)
Lactoferrin Musmusculus Bacteriocidal Membrane insertion, disruption (Liu et al. 2018)
Lysozyme Homo sapiens Bacteriocidal Membrane insertion, disruption (Wu et al. 2018)
Ovotransferrin Egg white Anti-fungal, anti-viral, anti-cancer,
anti-oxidative, anti-hypertensive
and immunomodulatory
Iron-binding and transport such that
iron is rendered unavailable for
microbial growth
(Chalamaiah et al. 2018)
Alpha-lactalbumin Milk protein Regulate lactose production in milk Upregulated expression in response
to prolactin
(Chalamaiah et al. 2018)
Beta-lactoglobulin Milk protein Physiological regulations and
anti-pathogenic activities
Iron binding through siderophores (Chalamaiah et al. 2018)




blocking NF-KB and MAPK
pathways
(Yamamoto et al. 2015)
AMP-P5 Drosophila
melanogaster
Anti-bacterial Membrane insertion and disruption (Tucker et al. 2018)
additives such as recombinant swine defensin and a
fly antibacterial peptide in the ratio 1:1 in juvenile
goats which lead to increased body weight, average
daily weight gain, improved enzymatic activity (pecti-
nase, xylanase, and lipase) and microorganism diver-
sity indices. However, further experimental research
is required to establish whether these effects are the
same for the human model. Two AMPs which belong
to the bacteriocins were reported, namely nisin and
pediocin PA-1/AcH, for their firm presence in line
with other natural food preservatives, either claimed as
an active substance in the formulation or being present
in a fermented active extract (Barbosa et al. 2017). This
has the potential to reduce the carcinogenic and other
side effects of some preservatives used in foods and
antibiotics.
AMPs are prone to contain certain amino acid
types, such as cysteine, proline, arginine, lysine, tryp-
tophan, and histidine which are rich in antimicro-
bial activities (Jia et al. 2016). There is sufficient evi-
dence that cysteine, tryptophan, lysine, and histidine
are essential amino acids that could be used to sup-
plement diet in humans. Cysteine-rich peptides are
particularly typical of plants (Ageitos et al. 2017) and
animals (Wang et al. 2017). Pairs of cysteines forming
intramolecular disulfide bridge are common in AMPs,
thus allowing a complex three-dimensional structure,
such as beta-sheets (Haney et al. 2017) and beta-turn
(Patel and Akhtar 2017).
The discovery and commercial development of
these peptides and the understanding of their
mechanism of action, resistance patterns, and smart
formulation strategies is an active area of research.
Formation of AMPs cyclization, inclusion of certain
amino acids and artificial analogs of amino acids,
and peptide mimetics with distinct structural back-
bones have also been reported to solve related prob-
lems of local delivery through degradation by pro-
teolytic enzymes (Bechinger and Gorr 2017). Fur-
thermore, blockage of N- or C-terminal ends of the
AMPs by modifications such as N-pyroglutamate,
N-acetylation, or C-amidation is frequently being
used to promote resistance toward peptidases (Kang
et al. 2017). These are some of the possible modifi-
cations through their use as food supplements. While
AMPs will probably not replace conventional antibi-
otics (Li et al. 2017), they may serve as a valuable asset
to already marketed drugs, especially in considering
safety features of these peptides such as biodegrad-
ability and lack of immunogenicity when added to
diets (Table 2).
Challenges of the use of AMPs as dietary
supplements
In spite of the numerous advantages of AMPs, cer-
tain challenges can hinder their applications in dietary
formulation which include high costs of production,
potential toxicity to humans (Wang 2017) and sen-
sitivity to proteases and extreme pH (Wong et al.
2017). Their lack of selectivity against specific strains
and folding issues of high molecular weight ones may
reduce their antimicrobial properties when AMPs are
used for surface coating (Baumann et al. 2017; Zhu
et al. 2017). This is whymany AMPs including the nat-
ural ones (such as magainins which are active in vitro)
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have high activities in animal models of infection only
at very high doses.
Conclusion
Antimicrobial peptides are invaluable molecules
whose potency suffers serious compromise by the inci-
dence and expansion of antimicrobial resistance. This
challenges their translation from non-clinical candi-
dates into successful clinical products and could be
enhanced by dietary influences as described by in
vivo studies. AMPs have properties which make them
promising alternatives to conventional antibiotics as
outlined in this review. The provision of AMPs in
animal foods strengthens a wide variety of therapeu-
tic purposes that include growth promotion. There-
fore, the discovery of more AMPs with their use as
AMP-diet supplement is imperative for improved sen-
sitivity, accuracy, and specificity to target pathogens
as it would enhance their therapeutic effect in over-
coming the shortcomings such as untimely degrada-
tion and reduced efficacy for effective combat against
resistant pathogens. With the aid of evolving technol-
ogy such as in silico technology and advancement in
knowledge, effective use of AMPs has the potential
to improve the efficiency of medical practitioners in
treating their patients through dietarymeans to reduce
side effect caused by antibiotics. However, there is a
need for research to evaluate the pharmacokinetics of
these AMPs due to the fact that the fate of AMPs in
vivo is still poorly understood.
Future perspectives
Natural and artificial sources of AMPs, including their
modes of actions, should be investigated more deeply.
More tools that can elucidate the structure–function
relationship of AMPs should be developed for efficient
synthesis and modification of AMPs. Although over-
exposure of microbes to high level of AMPs may bring
about resistance, this may serve as a good challenge to
randomize their use.
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